Cogent Biosciences Soars 19.69% on Institutional Buying

On May 13, 2025, Cogent Biosciences experienced a significant surge, rising 19.69% in pre-market trading, indicating strong investor interest and potential market momentum.

Recent developments have influenced Cogent Biosciences' stock performance. HSBC Holdings PLC's purchase of shares in the company has contributed to the positive sentiment, reflecting institutional confidence in Cogent Biosciences' future prospects. Additionally, Algert Global LLC increased its stake in the company by 92.3% during the fourth quarter, further bolstering investor optimism.

Analysts have also played a role in shaping market expectations. Louise Chen from Scotiabank maintained a Buy rating on Cogent Biosciences and set a price target of $17.00, highlighting the company's potential for growth. This positive outlook has likely encouraged investors to take a more bullish stance on the stock.